ATE447955T1 - Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel - Google Patents
Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittelInfo
- Publication number
- ATE447955T1 ATE447955T1 AT02796419T AT02796419T ATE447955T1 AT E447955 T1 ATE447955 T1 AT E447955T1 AT 02796419 T AT02796419 T AT 02796419T AT 02796419 T AT02796419 T AT 02796419T AT E447955 T1 ATE447955 T1 AT E447955T1
- Authority
- AT
- Austria
- Prior art keywords
- antitumoral
- cancer agent
- compounds
- piperazinone
- piperazinone compounds
- Prior art date
Links
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31479501P | 2001-08-24 | 2001-08-24 | |
| PCT/US2002/026881 WO2003017939A2 (en) | 2001-08-24 | 2002-08-23 | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE447955T1 true ATE447955T1 (de) | 2009-11-15 |
Family
ID=23221472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08105065T ATE530184T1 (de) | 2001-08-24 | 2002-08-23 | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe |
| AT02796419T ATE447955T1 (de) | 2001-08-24 | 2002-08-23 | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08105065T ATE530184T1 (de) | 2001-08-24 | 2002-08-23 | Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7763620B2 (de) |
| EP (2) | EP1427418B1 (de) |
| JP (1) | JP2005504771A (de) |
| AT (2) | ATE530184T1 (de) |
| AU (1) | AU2002332640B2 (de) |
| CA (1) | CA2458009C (de) |
| DE (1) | DE60234354D1 (de) |
| ES (2) | ES2335092T3 (de) |
| WO (1) | WO2003017939A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101086589B1 (ko) | 2006-06-28 | 2011-11-23 | 암젠 인크 | 글리신 수송자-1 억제제 |
| JP2011500767A (ja) | 2007-10-26 | 2011-01-06 | グラクソ グループ リミテッド | Ｐ２ｘ７モジュレータとしての４−ベンゾイル−１−置換ピペラジン−２−オン誘導体 |
| KR100967171B1 (ko) * | 2007-12-26 | 2010-07-05 | 재단법인서울대학교산학협력재단 | Δ5-2-옥소피페라진 유도체 및 그의 고체상 합성 방법 |
| CN102131784B (zh) * | 2008-06-24 | 2014-08-27 | 赛诺菲-安万特 | 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮 |
| WO2010088457A2 (en) * | 2009-01-29 | 2010-08-05 | H. Lee Moffitt Cancer And Research Institute, Inc. | Methods for inducing tumor regression, inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyltransferase i inhibitors |
| WO2010149943A1 (en) * | 2009-06-25 | 2010-12-29 | Oncorel Ab | New compounds and medical use |
| KR101162100B1 (ko) | 2010-01-19 | 2012-07-02 | 한미사이언스 주식회사 | 세포사멸 유도 활성을 갖는 신규 피라지논 유도체 및 이를 활성성분으로 포함하는 약학 조성물 |
| JP6023814B2 (ja) * | 2011-10-03 | 2016-11-09 | ユーロスクリーン エス．エー． | 選択的ＮＫ−３受容体拮抗薬としての新規なキラルＮ−アシル−５，６，７，（８位置換）−テトラヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法およびキラル合成 |
| EP3698797A1 (de) | 2017-10-16 | 2020-08-26 | Tsinghua University | -inhibitor des mevalonsäurewegs und pharmazeutische zusammensetzung davon |
| IL275337B2 (en) | 2017-12-15 | 2024-06-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopyrazine derivatives for cancer therapy |
| AR116020A1 (es) | 2018-09-03 | 2021-03-25 | Bayer Ag | COMPUESTOS DE 3,9-DIAZAESPIRO[5.5]UNDECANO COMO INHIBIDORES DE GGTasa I Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| WO2020048830A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048831A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
| US4251438A (en) | 1979-06-14 | 1981-02-17 | The Upjohn Company | Piperazinone and piperazine polypeptides |
| US5284828A (en) * | 1990-05-14 | 1994-02-08 | Fujisawa Pharmaceutical Co. Ltd. | Peptide compound and its preparation |
| CZ189197A3 (cs) | 1994-12-23 | 1998-01-14 | Dr. Karl Thomae Gmbh | Piperazinové deriváty, způsob výroby a farmaceutický prostředek s jejich obsahem |
| US5885995A (en) | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| PT951471E (pt) * | 1996-12-17 | 2004-08-31 | Warner Lambert Co | Inibidores cicloalquilo de farnesiltransferase de proteinas |
| EP1014984A1 (de) * | 1997-08-27 | 2000-07-05 | Merck & Co., Inc. | Prenyl-protein transferase inhibitoren |
| YU47600A (sh) * | 1998-01-27 | 2002-09-19 | Aventis Pharmaceuticals Products Inc. | SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa |
| JP2003529531A (ja) * | 1998-11-25 | 2003-10-07 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換オキソアザへテロシクリルＸａ因子阻害剤 |
| AU3247700A (en) | 1999-03-03 | 2000-09-21 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| RU2002105011A (ru) | 1999-07-28 | 2004-01-20 | Авентис Фармасьютикалз Инк. (Us) | Замещенные оксоазагетероциклические производные |
-
2002
- 2002-08-23 ES ES02796419T patent/ES2335092T3/es not_active Expired - Lifetime
- 2002-08-23 JP JP2003522462A patent/JP2005504771A/ja active Pending
- 2002-08-23 EP EP02796419A patent/EP1427418B1/de not_active Expired - Lifetime
- 2002-08-23 US US10/484,560 patent/US7763620B2/en active Active
- 2002-08-23 WO PCT/US2002/026881 patent/WO2003017939A2/en active Application Filing
- 2002-08-23 DE DE60234354T patent/DE60234354D1/de not_active Expired - Lifetime
- 2002-08-23 AU AU2002332640A patent/AU2002332640B2/en not_active Expired
- 2002-08-23 CA CA2458009A patent/CA2458009C/en not_active Expired - Lifetime
- 2002-08-23 EP EP08105065A patent/EP2014291B1/de not_active Expired - Lifetime
- 2002-08-23 AT AT08105065T patent/ATE530184T1/de not_active IP Right Cessation
- 2002-08-23 AT AT02796419T patent/ATE447955T1/de not_active IP Right Cessation
- 2002-08-23 ES ES08105065T patent/ES2376399T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7763620B2 (en) | 2010-07-27 |
| CA2458009C (en) | 2011-08-16 |
| EP2014291A3 (de) | 2009-06-17 |
| US20080221123A1 (en) | 2008-09-11 |
| EP1427418A2 (de) | 2004-06-16 |
| EP1427418B1 (de) | 2009-11-11 |
| EP2014291B1 (de) | 2011-10-26 |
| ES2335092T3 (es) | 2010-03-22 |
| AU2002332640B2 (en) | 2007-11-08 |
| CA2458009A1 (en) | 2003-03-06 |
| JP2005504771A (ja) | 2005-02-17 |
| EP1427418A4 (de) | 2004-11-17 |
| ES2376399T3 (es) | 2012-03-13 |
| DE60234354D1 (de) | 2009-12-24 |
| WO2003017939A3 (en) | 2003-11-13 |
| WO2003017939A2 (en) | 2003-03-06 |
| ATE530184T1 (de) | 2011-11-15 |
| EP2014291A2 (de) | 2009-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE447955T1 (de) | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel | |
| ATE506953T1 (de) | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel | |
| ATE555789T1 (de) | Pyridazinderivate und deren verwendung als therapeutische mittel | |
| ATE532772T1 (de) | Piperazinderivate und deren verwendung als therapeutische mittel | |
| DE60318013D1 (de) | N-oxid von n-phenyl-2-pyrimidinaminderivaten | |
| DE60143857D1 (de) | Zusammensetzung bestehend aus phy906 und chemotherapeutika | |
| BRPI0414908A (pt) | compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal | |
| MY129809A (en) | Quinazoline derivatives | |
| MEP36208A (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
| BRPI0407897A (pt) | derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios | |
| ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| CY1110316T1 (el) | Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους | |
| WO2003075850A3 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
| ATE433996T1 (de) | Humane dr4-antikörper und deren anwendungen | |
| DE60220771D1 (de) | Hemmer von cyclinabhängigen kinasen als mittel gegen krebs | |
| ATE337009T1 (de) | Medizinische verwendung thyromimetischer verbindungen gegen haarausfall und zusammensetzungen | |
| BR0201862A (pt) | Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos | |
| DE60117835D1 (de) | Amino- substituierte tetracyclische Verbindungen die als entzündungshemmende Mittel nützlich sind, und diese enthaltende Arzneimittel. | |
| ATE365735T1 (de) | Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| ID25478A (id) | Agonis 5-ht1f |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |